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ABSTRACT
INVESTIGATION OF IMPROVED
IMMUNOSTIMULATORY ACTIVITY OF D AND K
TYPE CpG ODNS IN LIPOSOMES
I˙hsan Dereli
M.S. in Molecular Biology and Genetics
Supervisor: Assoc. Prof. I˙hsan Gu¨rsel
August, 2013
CpG ODNs are potent immunotherapeutic agents. In human, two major
classes of CpG ODNs were shown to induce differential immune activation. D
ODNs are strong IFNα inducers, thus promising antiviral agents, whereas K
ODNs are effective against bacterial infections. However, their effects cannot be
combined. When K and D type ODNs are used simultaneously, K ODN cancels
D specific effect, a phenomenon known as K and D ODN dichotomy. The prime
reason for this counter acting K ODN action was subcellular compartmentalization
of K type CpG ODNs upon internalization. Besides, CpG ODNs have labile
nature. When investigated in clinical trials, these nucleic acid based ligands
are eliminated upon administration and displayed limited bio-availability due
to nuclease digestion. Hence, efforts to protect in vivo performance, and
increase stability and accumulation near target cells became a crucial task.
Liposome technology offers a simple and mild approach to harbor these ODNs
within membrane bilayers and protect them. We also reasoned that, if we use
liposomes that alter subcellular fate of K and D ODNs, we can retain both
K and D effect when liposomal ODNs are co-administered and the breadth of
immunotherapeutic spectrum could be improved. This thesis was designed to
understand and characterize different types of CpG ODNs loaded into different
liposomes and aimed to determine their activities in different in vitro and in
vivo settings. Our results revealed that when two different classes of clinically
important CpG ODNs were encapsulated within proper liposome types, it is
possible to recapitulate both K and D type ODN effect in PBMCs. Furthermore,
in a vaccine model against H. felis, although initially did not induce significantly
higher anti H.felis immunity, liposomal CpG ODNs improved persisting antibody
levels for extended periods compared to free counterparts. Collectively, our results
demonstrate that this platform allows more effective in vivo utilization of CpG
ODNs and can be formulated to develop more efficient means to combat several
health problems, ranging from cancer to allergy.
Keywords: Liposome, CpG ODNs, Helicobacter, Vaccine, D and K dichotomy.
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O¨ZET
LI˙POZOMLARA YU¨KLENMI˙S¸ K VE D CpG ODNLERI˙N
ARTAN I˙MMU¨N UYARICI ETKI˙LERI˙NI˙N
ARAS¸TIRILMASI
I˙hsan Dereli
Moleku¨ler Biyoloji ve Genetik, Yu¨ksek Lisans
Tez Yo¨neticisi: Assoc. Prof. I˙hsan Gu¨rsel
Ag˘ustos, 2013
CpG ODNler etkili immu¨noterapo¨tik ajanlardır. I˙nsanda iki ana ODN
sınıfının ayrık immu¨n aktivasyonları tetikledig˘i go¨sterilmis¸tir. D ODNler gu¨c¸lu¨
IFNα indu¨kleyicileri olarak o¨nemli antiviral ajanlar iken, K ODNler bakteriyel
enfeksiyonlara kars¸ı o¨ne c¸ıkar. Fakat, bu ODNlerin birlikte aynı anda uygulanması
c¸alıs¸maları D ODNe o¨zgu¨ etkilerin yok oldug˘unu go¨stermis¸tir. Bu olgu K ve D
ODNlerin zıt etkisi olaraka bilinir. Bu zıt etkinin en o¨nemli sebebi K ve D s
ODNlerin ic¸e alımı sırasında hu¨cre ic¸inde farklı kompartmanlara konus¸lanmasıdır.
Bundan bass¸a, kırılgan bir dog˘aya sahip olan CpG ODNler , bulas¸ıcı hastalıklar
ve alerjik semptomlar gibi belirli durumlara kars¸ı klinik denemelerde nu¨kleazlar
tarafından parc¸alandıkları ic¸in sınırlı etki go¨stermektedirler. In vivo etkisini
korumak , dayanıklılıg˘ını, hedef hu¨creler tarafından alınımını artırmak ic¸in bu
ajanları uygun tas¸ıyıcalara yu¨klemek o¨nem arz etmektedir. Lipozom teknolojisi
bu ODNleri c¸ift zar tabakası ic¸inde korumak ic¸in basit ve zararsız bir yaklas¸ım
sunmaktadır. Bundan bas¸k a, K ve D sınıfı ODNLerin hu¨cre ic¸indeki akıbetlerini
deg˘is¸tirebilen lipozomlara ayrı ayrı yu¨klenerek birlikte uygulanması ile K ve D
ODN etkisinin birles¸tirilebileceg˘ini o¨ngo¨rdu¨k. Bu tez farklı lipozomlara yu¨klenmis¸
deg˘is¸ik CpG ODNleri daha iyi anlamayı, karakterize etmeyi, in vitro ve in vivo
ortamlarda uygulamayı amac¸lamaktadır. Bizim sonuc¸larımız go¨stermis¸tir ki K ve
D sınıfı ODNleri uygun lipozomlara yu¨kleyip iki tip ODN etkisini de insan kan
periferik kan hu¨crelerinde go¨rmek mu¨mku¨ndu¨r. Bundan bas¸ka lipozomal CpG
ONDNler H. felis as¸ı modelinde, bas¸ta daha iyi performans go¨steremeseler de,
daha uzun su¨reli antikor u¨retimi sag˘lamıslardır. Dolayısıyla, nu¨kleik asit tabanlı
TLR ligandlarının in vivo etkisini klinik ortamda iyiles¸tiren bu platform, kanserden
alerjiye bir c¸ok sag˘lık problemine kars¸ı daha etkili tedaviler gelis¸tirilmesi ic¸in
kullanılabilir.
Anahtar so¨zcu¨kler : Lipozom, CpG ODN, Helikobakteri, As¸ılama, K ve D kars¸ıt
etkileri.
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Chapter 1
Introduction
1.1 The Immune System
History of earth and the course of evolution have been and are being influenced by
continuing competition between organisms. As such, one of the most striking
and interesting race happens between pathogens and their hosts. Pathogens
persistently and relentlessly try to insult host organisms. Therefore, all living
organisms developed means to protect themselves from pathogens. Those defence
systems are usually multilayered and interrelated and most of the time complexity
differs from each other. Even certain bacterial species have developed complex
defense system against phage infection [1] . In higher organisms, collection of
multiple defense mechanisms is called the immune system.
In mammals, although the exact content may vary, protection against
pathogens starts with a natural barrier the skin, which is followed by mucosa.
Mucosa do not only form a simple physical barrier, but is a crucial element of
immune system, as it harbours a special site for mucosal immunity. Mucosal
immunity has particular importance, as it covers the largest area in body that
continuously encounter with gut or respiratory pathogens and therefore mucosal
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immunity is an important branch of the innate immune system [2]. Innate immune
cells are the second barrier that pathogens must breach. Working principle of
innate immunity is generic, and a very unique one. Innate immunity exploits the
one of the oldest mechanisms that organisms developed to survive; discriminating
between self and non-self by recognizing unique molecular structures. Charles
Janeway introduced the pattern recognition model for immune activation in his
historical talk [3]. As mentioned above, there is a constant race between hosts
and pathogens. Since pathogens has an advantage in terms of rate of evolution,
mammalian innate immune system learned to differentiate evolutionary conserved
Pathogen Associated Molecular Patterns (PAMPs), such as lipopolysccharide
(LPS) lipoteichoic acid (LTA) or certain peptidoglycans (PGN) that are not
expressed by self but only expressed by pathogens via germline encoded pathogen
recognition receptors (PRRs) [4]. ). A few years later, Polly Matzinger extended
Janeway’s postulation by proposing the ability of the innate immun system
to discriminate between normal and pathological host sites [5], namely, The
Danger Theory. Her model includes PRR recognition of Damage Associated
Molecular Patterns (DAMPs), which are found in hosts normally and initiates
immune reaction in disease conditions [6]. Once innate immunity is activated, an
inflammatory response is ensued to eliminate the persisting infection.
Adaptive immune system, or acquired immune system function cooperatively
with innate immune system to eliminate persisting pathogens despite of initial
attempts of innate immunity. In fact, adaptive immunity needs to be activated
by innate immunity. When innate immunity is activated by pathogens,
antigen-presenting cells (APCs) of the innate immune system, which resides within
peripheral tissues in immature state, quickly phagoctose microbes or infected cells.
Fragmented microbial peptides are loaded onto major histocompatibility complex
(MHC) class I or II molecules and displayed on surface of APC cells. MHC class
I and MHC class II molecules presents those microbial peptides to CD8 and CD4
T cells, respectively At the same time co-stimulatory proteins CD80 and CD86
on surface of APCs are upregulated, which enables naive T cell activation in the
lymph node [7]. A scheme covering basics of antigen presentation is showed in
3
Figure 1.1.). As innate immunity cope with conserved structures of pathogens
to overcome infection while developing no specific memory, adaptive immunity
requires diversity in order to deal with vast range of pathogenic repertoite which
are already exposed to innate system. In the naive state of T and B cells,
upon encountering an antigenic determinant, a series of somatic recombination
of genes that encode antigen receptors; T cell receptor (TCR) and B cell receptor
(BCR) is initiated. This system allows generation of vast numbers of different
receptors, specific to each epitope, with different specificity. When an antigen
receptor is stimulated by an APC, the cell that receptor belongs to undergoes
clonal expansion, rapid proliferation and commitment. This state is known as
the formation of effector T and/or B cells, and at this stage, they are out of
their naive state. B cells, however, cannot be activated de novo by APCs. They
require a sub-population of T cells called T-helper cells for activation. TCRs
and soluble BCRs (antibodies) specific for a peptide epitope portion of microbial
antigen eventually help elimination of the insulting organisms. Adaptive immunity
is specific and long lasting, due to establishment of B and T cells memory.
1.2 Innate Immune System
Innate immunity is the first line of defense of the immune system and composed
of several different systems and cell types. As mentioned above, mucosal immune
system covers the largest area that body encounters with pathogens or harmful
substances. Some major components worth mentioning includes intestines,
bronchial airways, mouth and mucosal surfaces. Moreover, epithelial tissues
secretes mucosa that forge a natural barrier and antimicrobial peptides against
invading pathogens [10]. Mucosal immune system also hosts several specialized
immune cell types, such as mucosal-associated invariant T lymphocytes (MAIT)
[11]. Thus, innate immunity provides first physical and chemical barriers against
pathogens [12].
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Figure 1.1: Activation of DC upon Ag internalization and presentation of epitopes
to T and B cells. Adapted from [8, 9]
Innate immune system cells are challenged by diverse range of pathogens and it
must have ability to deal with different complications. Therefore, immune system
has cell types that are able to accomplish different tasks in case of an infection.
Major cell types of innate immune system are phagocytes (i.e. neutrophils,
monocytes/macrophages, DCs ), natural killer (NK) cells, mast cells, eosinophils
and basophils.
NK cells destroy cells that lack MHC I molecule on their surface. All host
cells normally express MHC I molecule on their surface, which prevent NK cells to
attack host cells. In case of viral infection [13], or tumor growth [14, 15], MHC I
molecule is downregulated and along with additional signals, NK cells recognizes
and kills those altered host cells.
Mast cells, eosinophiles and basophiles are characterized by granules in their
cytoplasm, and they are commonly called as granulocytes. Those granules are
5
histamine and heparin rich, along with chemokines and toxins. Upon infection, the
contents of granules are released into environment. Histamine causes vasodilation
and recruits other immune cells to site of the infection. Chemokines are also
important for recruitment of other immune cells. Toxins are effective measures
against pathogens. However, granulocytes are double edged swords of immune
system, as they have active roles in allergic diseases [16, 17, 18]
Neutrophiles, monocytes/macrophages and dendritic cells are defined under
common term phagocytes, due to their very alike working mechanisms when they
encounter with pathogens. Neutrophils are the first cells that arrive the site of
infection, and they help elimination of pathogens by releasing toxins or generating
reactive oxygen species, such as hydrogen peroxide (H2O2), a process known as
respiratory burst). Macrophages are mature monocytes and both cell types utilize
a similar system to eliminate pathogens. Macrophages differ from blood circulating
monocytes as they reside on tissues. Arguably, macrophages are the most efficient
type of the phagocytes, due to their ability to ingest large number of microbes.
Dendritic cells are also digest microbial particles or infected cells. But their main
role is not elimination of infection, rather antigen presentation to T cells, thereof
mature dendritic cells are called the sentinel antigen presenting cells (APCs).
Immature dendritic cells circulate through body. When an infection occurs, they
migrate to site of infection, phagocytose pathogens or remnants of infected cells.
They process microbial particles so that TCRs can bind them, remove them to
their surfaces and present to T cells. Along with co-stimulatory molecules, this
entire procedure ensures proper activation of T cells, consequently activation of
adaptive immune system.
One major element of the innate system is the complement system.
Complement system is actually a cascade of soluble proteins. Once this cascade is
activated by presence of pathogens, complement system proteins are sequentially
cleaved. Final product forms a pore structure in the membranes of pathogens,
causing rapid lysis of the pathogens. Marking the pathogens via opsonization and
attracting macrophages and neutrophils via chemotaxis are other crucial functions
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of complement system.
Apart from cells and complement system, innate immune system is
characterized by initiation of inflammation, a rapid and strong mechanism that
prevents spread of infection. Inflammation is started by recognition of pathogens,
through their PAMPs PRRs. PAMPs are reliable source to identify pathogens,
due to their evolutionary conserved structures, presumably because they are
vital for pathogens survival or function. Inflammation can be described as, and
much precisely, concerted activation of immune system through communication of
immune cells via chemokines and cytokines. Chemokine and cytokine secretion
leads to migration of granulocytes, macrophages and dendritic cells, along with
other immune cells, to the site of infection. Thereafter, immune cells try to
eliminate the infection. However, once more, everything starts from recognition of
pathogens by innate immune cells..
1.2.1 PAMPs and PRRs
As already mentioned numerous times, PAMPs of pathogens are recognized
by PRRs of immune cells. PAMPs are evolutionary conserved and invariant
structures among broad range of organisms belong to microbial world. PRRs
are germline-encoded relatively small group of receptors that are highly expressed
by immune cells.
Lipopolysaccharide (LPS), peptidoglycan (PGN), lipoteichoic acids and
cell-wall lipoproteins, fungal cell wall product B-glucan, unmethylated
cytosine-phosphate-guanine (CpG) motif rich bacterial genomic DNA, yeast
zymosan, viral single and double stranded RNAs (ssRNA and dsRNA), are among
widely studied PAMPs [4, 12, 19].
Some PRRs are secreted to body fluids. Mannan-binding lectin, C-reactive
protein (CRP), and serum amyloid protein (SAP) are well known examples
[20]. A group of PRRs are classified as cytoplasmic PRRs. Nucleotide binding
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oligomerization domain (NOD)-like receptors (NLRs) and retinoic acid-inducible
gene I (RIG)-like helicases (RIHs) are cytoplasmic PRRs [4]. NLRs are mainly
responsible for detecting bacterial or viral components, while RLRs s and TLRs
can recognize variety of PAMPs [20, 21]. A summary of PAMPs and PRRs is given
in Table 1.1
Table 1.1: Pattern recognition receptors and their ligands. Adapted from Ishii et.
al. [19]
Microbial Signature TLRs RLRs NLRs CLRs
Viruses Structural proteins (capsid,
envelope proteins)
TLR2, TLR4
DNA TLR9 FcγR
RNA TLR3 (dsRNA),
TLR7,
TLR8 (ssRNA)
RIG-1,
MDA5,
LGP2
NALP3 FcγR
Bacteria Cell wall components, LPS,
PGN, lipoteichoic acid,
lipoproteins
TLR2/1,
TLR2/6, TLR4
NOD1,
NOD2,
NALP1,
NALP3
Collectins
(MBL)
Flagellin TLR5 IPAF,
NAIP5
Perotoxins NALP3
DNA TLR9 ASC
RNA NALP3
Protozoan
parasites
GPIs TLR2, TLR4
Malaria hemozoin TLR9
Proteins (T. cruzi Tc52,
profilin)
TLR2, TLR11
DNA TLR9
Helminths Lipids TLR2
RNA TLR3
Fungi Cell wall components
(GlcNAc, mannan, β-glucan)
TLR2, TLR4,
TLR6
Mannose
receptor,
DCSIGN,
Dectin-1,
Dectin-2,
CARD9
DNA TLR9
TLR: toll like receptors, RLR: RIG like receptors, NLR: NOD like receptors, CLR: C-type
Lectin like receptors
TLRs are the most abundantly and extensively studied PRR family. Toll
was originally identified in Drosophila (fruit fly) as an important molecule for
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embryonic development [22]. Later on, it was revealed that a group of molecules
which are associated with immune activation have surprising homology with Toll
[23]. Not long after, immunogenic role of Toll was discovered and termed as
Toll-Like Receptors (TLRs) in humans and mice have arisen as important immune
system factors [24] . TLRs are members of IL1R superfamily and they contain
ectodomain leucine-rich repeats (LRR) that mediate the recognition of PAMPs,
a transmembrane region, and intracellular Toll-IL-1 receptor (TIR) domains that
mediate downstream signaling pathways. They can reside on cell surface, as well
as intracellular compartments (Figure 1.2).
Figure 1.2: Cell surface and endosome associated TLRs with their representative
ligands. Note that some TLRs requires dimerization for their activation via their
ligands. Adapted from Takeda and Akira [25]
1.2.1.1 Cell Surface Toll-Like Receptors
TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 (only in mice) are positioned on the
cell surface. They are mainly responsible for recognizing microbial cell membrane
molecules. TLR2 is usually forms heterodimers with TLR6 or TLR1 [26].
Therefore, those heterodimers and TLR2 itself has ability to recognize PAMPs that
belong to diverse range of species [26]. In general, Triacylated lipopeptides signal
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through TLR1-TLR2 heterodimers, while diacylated lipopeptides signal through
TLR2-TLR6 heterodimers, although it is also suggested that not only lipid moiety
but also peptide part is responsible for determining ligand-receptor interaction in
hosts [27]. Ligands of TLR2 include LTA and PGN from Gram-negative bacteria,
Zymosan from S. cerevisae and lipoarabinomannan from Mycobacteria or the
hemagglutinin protein from measles virus [19].
TLR4 is one of the earliest identified TLRs and co-receptor for LPS [28]. It
was demonstrated that TLR4 mediates the LPS responsiveness in TLR4 deficient
mice, which were hyporesponsive to endotoxin challenge [25, 29]. ). Later studies
discovered that, TLR4 actually is a co-receptor and LPS mediated signaling
requires activation and collaboration of other molecules as well, such as CD14
and LPS binding protein (LBP) [30].
TLR5 recognizes bacterial flagellin. Flagellin is an important protein for
bacterial motility [31]. Indeed, TLR5 is expressed on the basolateral side of the
epithelia, but not on the apical side, which explains why only invading microbes,
not commensal bacteria induce an immune response [32].
TLR11 is not present in humans, but present in mice and have a role in
recognizing bacteria that infects bladder and kidney as it is highly expressed
in bladder in kidney [33]. Additionally, protozoan profilin-like protein (i.e.
toxoplasma gondii) is one of the major ligands for TLR11 [4, 34].
1.2.1.2 Intracellular Toll-Like Receptors
TLR3, TLR7 and TLR8 (functional only in human), TLR9 and TLR10 [25]
are found in intracellular compartments (REFS). TLR3 recognizes dsRNA and
ssRNA which are common and important intermediate products of viral replication
[35]. Since TLR3 is positioned on intracellular compartments, it is also evident
that TLR3 has important role against viral infection [36].The synthetic dsRNA
analog polyinosinic-polycytidylic acid (polyIC) is an important candidate antiviral
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reagent, due to its ability to activate TLR3 signaling [37].
TLR7 and TLR8 recognize ssRNA. Genomes of many RNA viruses are ssRNA
and they were shown to be activated by RNA virus infection [36]. TLR7 is highly
expressed in pDCs and upon activation of TLR7 signaling pathway, expression of
antiviral type IFNs, most notably IFNa is induced in pDCs [38]. A prominent
immune modifier and anti-viral reagent, resiquimod R848 (guanine nucleotide
analog), is in fact a synthetic ligand of TLR7 [39]
TLR9 recognizes unmethylated CpG motifs. In addition to CpG suppression,
mammalian genome contains methylated CpG residues. Of note, bacterial
genome represent 25-30 fold more unmethylated CpG dinucleotides compared to
mammalian genome. [40]. While physiological role of TLR9 is certainly significant,
most of the literature is related to the immunotherapeutic applications of TLR9.
Certain types of synthetic CpG ODNs can induce type I IFN secretion, while other
CpG types are potent pro-inflammatory cytokine inducers [41]. It should be noted
that many factors affect the final outcome, such as pH, compartmentalization, and
sequence of CpG ODN along with their structure. [42, 43, 44]
1.2.1.3 TLR Signaling Pathway
TLRs share many common elements in their signaling pathway. However, due
to minor but essential differences, each TLR has specific response. TLRs can
alter gene expression profile of host cells dramatically, via activating transcription
factors such as NF-κB and IRFs. One of the earliest TLR downstream effector
proteins was myeloid differentiation primary response gene 88 (MyD88). Later
studies conceived that TLR3 signaling is MyD88-independent-TRIF dependent
pathway and TLR4 signaling is possible through both pathways.
1.2.1.3.1 MyD88 Dependent Pathway: M MyD88 associates with the TIR
domain of TLRs. Its importance for TLR signaling has been shown in MyD88
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deficient mice, which are unresponsive to various TLR ligands [45, 46]. MyD88 is
an adaptor protein that recruits IL-1 receptor associated kinases (IRAK) IRAK-1,
IRAK-2, IRAK-M and IRAK-4 [47]. IRAK-2 and IRAK-M are inactive (36).
IRAK-4 phosphorylates IRAK-1 [48] and activated IRAK1 interacts with TRAF6.
Both AP-1 transcription factors and NF-κB transcription factor are activated by
TRAF6 through distinct pathways. AP-1 TFs activation is induced by MAP
kinases in which TRAF6 initiates the signal cascade. Concurrently, TRAF6 is
involved in IKK mediated degradationof IKB, and NF-κB nuclear localization as
a consequence, via activation of TAK1-TAB complex.
1.2.1.3.2 MyD88 Independent-TRIF Dependent Pathway: Possibility
of a MyD88 independent TLR pathway was arisen when NF-κB nuclear
localization was not halted but delayed in MyD88 deficient mice in response to
LPS; although no cytokine expression was observed [45]. It seemed that TLR4
was able to induce signaling pathway regardless of MyD88, a defective one though.
Further studies revealed that TLR3 also has a MyD88 independent pathway,
but unlike TLR4, TLR3 completely relies on MyD88 independent pathway [49].
Instead of MyD88, TRIF and related protein TIRAP act as adaptor protein and
mainly induces type I IFN expression via activation of IRF3. NF-KB signal was
also affected by TRIF-dependent pathway.
1.3 Synthetic CpG ODNs
Immunostimulatory properties of CpG containing bacterial DNA was discovered in
1995 [51]. Later on, immunomodulatory effects of CpG ODNs are widely studied.
CpG ODNs can be used as effective vaccine adjuvant, with relatively low adverse
effect profile [52]. Consequently, two distinct classes of ODNs, Class A or D and
Class B or K type ODNs were identified with differential activation of immune
system. Regardless of their differences, distinct classes of CpG ODNs share some
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Figure 1.3: Initiation of MyD88 and TRIF dependent signaling cascade upon
TLR-ligand interaction. Adapted from [50]
common properties; minimum required length for immune stimulation is 8 bp,
in optimum sequences, unmethylated CpG nucleotides are flanked by PuPu and
PyPy bases in mice and PuPy and PuPy in humans, despite significant homology
between murine and human TLRs (over 75 % homology exists). Finally, partial
or complete modified backbone to reduce nuclease attack is necessary for specific
classes to induce an immune activation.
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1.3.1 A or D Type ODN
This class of ODNs (D ODN hereafter) has been characterized with partially
modified backbone and polyG runs at the ends (i.e. PolyG-PS/PO/PS-PolyG).
Palindromic sequences that are located before and after CpG nucleotides cause
secondary structure formation. Assembly of two or more D type ODN via Hogstein
Base pairing of Poly G caps also leads to formation of heterogeneous higher order
structures. Of note, these concatamers are necessary for the D-ODN activity. It
was also shown that palindromic sequences and polyG runs are crucial for D type
ODN activation [53]. Macromolecular aggregation of D ODNs is recognized by
scavenger receptor CXCL16 and causes localization of D type ODNs into early
endosomes. Thereafter, D type ODNs directly promote strong and prolonged IFN
and IFN expression from pDCs [54]. D-ODN also indirectly induce IFN and IP-10
from PBMC and contribute to NK cell-mediated cytolytic activity [55]. Activation
of costimulatory molecules CD86 and CD80 somewhat moderate, an D type ODNs
are weak inducers of pDC maturation [54].
1.3.2 B or K type ODNs
B or K type ODNs (K ODN hereafter) have fully phosphorothioated backbone.
They do not have internal palindromic sequences or polyG tails. Usually 2-3 CpG
motifs are required for optimum activity [56]. Unlike D type ODNs known as
a strong type 1 IFN inducer, K type ODNs can induce very little if any IFN
expression. However, they are very potent inducers of proinflammatory cytokines
IL6 and IL12 from mouse spleen cells [57]. They also promote rapid maturation
of pDCs. In physiological conditions, K type ODNs remain linear and do not
aggregate.
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1.3.3 Other Types of CpG ODNs
Two main CpG ODN types have different immune stimulatory properties. Many
novel CpG ODNs were defined that try to recapitulate both D type and K type
specific immune activation. For example C type ODN can induce both TNFa
and IFNa from albeit lower than K ODN and D ODN respectively [58]. It has
structural similarities with both type of ODNs; fully phosphorothioated backbone
like K type ODNs and internal palindromic sequences like D type ODNs [59]. C
type ODN captures properties of both K and D type ODN, but not at desirable
rate. Many other novel CpG ODN types are defined, such as Y shaped ODN [60],
however, their exact immunomodulatory natures yet to be cleared.
1.3.4 Competitive Action of Mechanisms of D and K Type
ODNs
As mentioned above, K type and D type ODNs display a dichotomy in terms of
immune stimulatory activities. Due to its ability to form higher order structures,
recognition of D type ODNs through TLR9 requires CXCL16 involvement, a
scavenger receptor. D type ODNs localize to early endosomes after CXCL6
mediated recognition, which leads to co localization of MyD88 and interferon
regulatory factor-7 (IRF7) [61]. Subsequent events promote IFN secretion
from pDCs, and IFN secretion from mouse spleen cells, which are inducers of
cell mediated immune response. K ODNs preserve their linear structure in
physiological conditions. Therefore, their recognition through TLR9 is CXCL16
independent. K ODNs are quickly localizes to late endosome and induces TNFa
secretion from pDCs and leads to pDC maturation [62], eventually humoral
immune activation [7]. Even though both CpG ODN types hold promising vaccine
adjuvant properties, it is desirable to capture both types of immune regulatory
properties in one single formula. Unfortunately, simultaneous administration of D
and K type ODNs are not possible. Although they do not inhibit their binding,
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uptake and localization kinetics, K type ODN inhibits D type ODN dependent
activation [62, 63]. While K type ODN acts on both B-cells and pDCs, D type
ODN only act on pDCs. D type ODN localizes to early endosome and induces IFNa
expression. K type ODN localizes to late endosome induces TNFa secretion and
promotes pDC maturation, thereby prevents IFNa secretion from pDCs [62, 63].
Figure 1.4: Differential immune activation of human pDC following D and K
triggered signaling cascade. Adapted from [64]
K type ODN entered many clinical trials; however, D ODN entered few. D
ODN has ability to spontaneously form heterogeneous high ordered structures.
This uncontrollable nature of D ODN prevents its GMP production and FDA
permission. Only administration via particles that can stabilize D type ODN can
lead to clinical trials [65]. Therefore, new approaches have been trying to overcome
this problem. One possible method is designing K-like ODNs that can have D type
effects, as mentioned in previous section. Another method would be administration
of K type ODNs embedded cationic lipid particles, which can helps localization of
K type ODNs to early endosomes instead of late endosomes and IFN production
[55].
16
1.4 Helicobacter Vaccine
Helicobacter is a helix shaped gram negative genus of bacteria. Some species
have been found in gastrointestinal track of mammals and birds. It is estimated
that 45-50 % human population was infected with Helicobacter pylori (H. pylori),
major infectious species in humans [66]. Although 85 % percent of the cases are
reported to be asymptomatic, in the remaining cases colonization in the gastric
lumen causes persistent inflammatory response, which eventually leads to gastritis
(64). Non-pathogenic strains have been found to lack Cag pathogenicity island in
their genome [67]. Helicobacter can survive in low acidic environment of gastric
lumen by producing large amounts of urease and neutralizing acid [68]. Urease
breaks down the urea to carbon dioxide and ammonia, which is a basic molecule
and helps helicobacter survival in such extreme condition [69]. H. pylori is also
able to use chemotaxis to move away from low pH lumen into mucosal surface of
epithelia, which has considerably more neutral pH [70] owing to multiple flagella
[71].H. pylori flagellin is able to evade TLR5 [72].
Treatment of H. pylori associated gastritis was aimed by combined antibiotic
and proton pump inhibitor treatment in mid 1990′s [73], since then this treatment
modality is still used in the clinic [74]. In case H. pylori and complications are
not eradicated, stronger antibiotics are used [74]. However, increasing antibiotic
resistance of H. pylori strains became a major problem in recent years and infection
has proved difficult to cure [75]. Besides, patient compliance and recurrent
infections are often causes problems [76]. Therefore, development of vaccine
against H. pylori is currently taking a lot of scientific attention.
1.4.1 Helicobacter Infection
Developing vaccine against H. pylori brings unique challenges. Unlike blood borne
pathogens or viral infections, H. pylori infection and subsequent inflammation
should be studied in mucosal immunity [77]. Due to its distinct dynamics, vaccine
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development related to mucosal immunity should be handled separately [78, 79].
This is a further obstacle for development of efficient vaccine formulations against
H. pylori. Another difficulty is lack of a proper animal model. Until Lee et al.
introduced Helicobacter felis, a Helicobacter species isolated from cat, there were
no gold standard mouse model for studying in vivo H. pylori infection [80, 81],
although it is now possible to use H. pylori in mouse model [?, 81]. Furthermore,
finding a proper and non-toxic mucosal adjuvant, efficient route of administration
is another great challenge [82]. Nowadays, those adversities have been fairly
overcome. Clinically, it was shown that H. pylori infected individuals were able
to produce IgG antibody against H. pylori antigen [83]. IgA class antibodies are
prime antibody type in mucosal linings and have critical role in mucosal immunity
[84]. Indeed, oral delivery of microparticles encapsulating H. pylori lysates can
induce IgA and IgG production in mice [85]. Using live vectors that express H.
pylori related genes is another approach. This method uses a non-pathogenic
bacteria as a vector and is reported to induce significant IgA production and
reduced H. pylori colonization after challenge [86]. The above mentioned two
methods have serious drawbacks, as there is no reliable data regarding to protective
effect of the vaccine for the former and non-specific immune response due to live
vector for the latter. There are also studies with conventional adjuvants, such as
cholera toxin [87], but they are not feasible options for humans. CpG ODNs are
highly effective adjuvants with minimal adverse effects. It is not surprising that
last couple of years CpG ODNs are included in efforts to develop vaccine against
H. pylori [88, 89, 90]
1.5 Liposome Technology
Liposomes are artificial vesicles composed of one or more lipid bilayers, which
enclose aqueous compartments between bilayers and core aqueous phase [91].
Interior sides of lipid bilayers and inner aqueous compartments have hydrophobic
and hydrophilic nature, respectively. This reciprocal feature of liposomes and
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versatility in manufacturing are prime reasons for developing liposome-based
technologies. Following seminal observation by Alec Bangham in mid 1960s; that
lipids can form spherical structures in aqueous environments [92], Gregoriadis
and Ryman for the first time successfully loaded these vesicles with proteins and
injected in vivo and observed their fates [93].
Liposomes can exists in varying sizes, lipid composition, net charge and
structure. Changing lipid composition can dramatically alter physicochemical
properties of liposomes [94]. Lipid bilayers can be single or more, in case of
single bilayer, liposome is called unilamellar, and multilamellar in case of latter.
Liposomes ranging 0.5 uM and 4-5 uM is called large vesicles, bigger and smaller
vesicles are called giant vesicles and small vesicles, respectively. Small unilamellar
vesicles (SUVs) and large multilamellar vesicles (MLVs) are commonly used
liposomes for pharmaceutical purposes, [95] whereas giant unilamellar vesicles are
perfect model lipid membranes [96, 97]. SUV on the other hand are suitable either
as transfection reagents or as imaging agents [98].
Liposomes are biocompatible vesicles and can entrap both hydrophobic and
hydrophilic molecules in lipid bilayers and in aqueous compartments, respectively.
This gives a broad range of materials that can be entrapped into liposomes.
Unlike free administered drugs, liposomal drugs localize inside the cells and
even inside cellular compartments more efficiently [99]. Moreover, liposomes
protect their biological cargoes from nuclease and protease degradation [100,
101, 102]. Engineering liposomes is easy and intended to overcome possible
problems during drug delivery. One such modification of liposomes is attaching
polyethyleneglycol (PEG) to the liposomes, via either covalent bonding to lipids
or embedding PEG containing molecules into lipid bilayers using hydrophobic
moieties. PEGylated liposomes are called stealth liposomes since they are less
susceptible to elimination from serum and elimination by reticuloendothelial
system (90, 91). It is also possible to manufacture targeted liposomes by attaching
in order to increase liposomal drug accumulation to the desired tissue or cell
type [98, 103] (FIG-LASIC). Targeted liposomes are manufactured by attaching
19
molecules that are able to recognize specific sites in target tissue or cell, Igs most of
the times. It is also possible to profit both stealth and targeted liposome delivery
by covalently attaching antibody fragments that lack Fc portion to the PEG chains
[101].
Figure 1.5: Frequently used liposomes for therapeutic purposes; conventional,
cationic, stealth and targeted liposomes. Adapted from Lasic (1997) [104]
1.5.1 Liposomal Vaccines
Liposomal vaccine formulations are capable of combining two signals in one package
that is a necessary step to achieve therapeutic vaccination (i.e. antigen plus
adjuvant). In fact, liposomes can have their adjuvant effects in certain formulations
[105, 106]. Hence, liposomes are among promising candidates for new generation
vaccine formulations [107]. A phase IIB clinical trial for liposomal L-BLP25
peptide, which is a fragment of a highly expressed glycoprotein in common
cancers, against non-small lung cancer showed that liposomal vaccine formulation
significantly increased median survival rate [108]. It is also worth mentioning,
co-encapsulation of the antigen and adjuvant into single liposomal compartment
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can boost the performance of vaccine formulation [109]
TLR ligands were also used as liposomal adjuvants [110, 111], nucleic acid
based TLR ligands in particular, due to ease of their incorporation into cationic
liposomes. Cationic liposomes that co-encapsulated poly(I:C) and synthetic cord
factor is shown to induce CTL dependent tumor regression [112]. In another
study, co-encapsulation of different TLR ligands (poly(I:C) and CpG ODN) into
anionic liposomes was proven to induce TH1 biased immunity and robust response
against antigen ovalbumin, despite possible steric hindrance [?]. Hence, liposomal
vaccine formulations containing nucleic acid based TLR ligands as adjuvants
clearly demonstrated encouraging results, which support further studies.
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Chapter 2
Aim of The Study
CpG ODNs are potent immunotherapeutic agents and already appeared in clinical
trials for variety of purposes. Liposomal delivery systems are also extensively
utilized. In the first part of this study, we aimed to investigate in vitro
performance of different types of liposomes that encapsulated CpG ODNs in a
mouse macrophage cell line and spleen cells. Best performing formulations were
tested in a H. felis vaccine model. Up to date, there is no other study that tries
to combine liposomal vaccination methods and CpG ODNs.
K and D type ODNs have distinct immune stimulatory properties. A good
immunenotherapeutic reagent would have both ability. However, differential
immune activation mechanisms of K and D type ODNs due to their subcellular
fates are major hamper for their simultaneous administration. Despite efforts to
overcome this problem, there are no successful solution. In the second part of this
study, our purpose was to alter subcellular localization of D and K types ODN
by encapsulating them into liposomes in order to to recapitulate their individual
effect on human PBMCs when they were administered simultaneously.
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Chapter 3
Materials and Methods
3.1 Materials
3.1.1 ELISA Reagents
Mouse cytokine ELISA reagents, including monoclonal catching antibody,
biotinylated reporter antibody, recombinant cytokines and streptavidin-alkaline
phosphatase (SA-AKP) were purchased from BioLegend (USA). SA-AKP
substrate p- nitrophenyl phosphate disodium salt (PNPP) was purchased from
Thermo (USA). Mouse Immunoglobulin ELISA reagents; goat anti-mouse IgG,
IgG1, IgG2a monoclonal antibodies conjugated with alkaline phosphatase (AKP)
were obtained from Southern Biotech (USA). Human cytokine ELISA reagents for
IL6 and TNFα were from Biolegend (USA). For IFγ and IFN-a2α, reagents were
purchased form BD (USA) and MabTech (USA) respectively.
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3.1.2 TLR Ligands
CpG ODNs (TLR9 ligand) were either synthesized by Alpha DNA (Montreal,
Canada). or synthesized in Therapeutic ODN Research Lab (THORLab) (Bilkent,
Ankara, Turkey) with a MerMade6 Oligonucleotide Synthesizer. Peptidoglycan
(PGN) (isolated from B.subtilis) was from Fluka (Switzerland), lipopolysaccharide
(LPS) which was isolated from E. coli was from Sigma (USA). Detailed informaiton
on CpG ODNs were given in Table 3.1.
Table 3.1: List of Oligonucleotides that are used in this thesis. Capital letters
denote a nucleotide with phosphorothioate backbone and those in lower cases show
phosphodiester backbone. K3, K23 and 1555 are K type ODNs whereas D35, 1466
and D3CG are D type ODNs
K3 (20mer) 5′-ATCGACTCTCGAGCGTTCTC-3′
K3 Flip (20mer) 5′-ATGCACTCTGCAGGCTTCTC-3′
D35 (20mer) 5′-GGtgcatcgatgcaggggGG-3′
D35 Flip (20mer) 5′-GGtgcatgcatgcaggggGG-3′
K23 (12mer) 5′-TCGAGCGTTCTC-3′
1555 3cg (20mer) 5′-GACGTTGACGTTGACGTTGG-3′
1466 Acore MB (16mer) 5′-TCaacgttgattcaAA-3′
D3CG MB (20mer) 5′-GGtcgatcgatcgaggggGG-3′
3.1.3 Lipids
Cholesterol was purchased from Sigma Aldrich (USA). L-α-Phosphatidylcholine
(PC), 3α-[N-(N’,N’-Dimethylaminoethane)-carbamoyl] Cholesterol Hydrochloride
(DC-Chol), 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N- [Methoxy(Polyethylene
glycol)-2000] (Ammonium Salt)(PEG-PE), 1,2-Dioleoyl-sn- Glycero-3-Phosphoethanolamine
(DOPE) were all from Avanti Polar Lipids (USA).
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3.2 Methods
3.2.1 Cell Line Maintanence
RAW 264.7 cell line, murine macrophage-like cells were cultured in 10% FBS
supplemented complete RPMI-1640 media. Medium was changed every 2-3 days.
Upon reaching 80% confluency, cells were passaged with 1:3 ratio or used for in
vitro stimulation.
3.2.2 Stimulation of RAW 264.7 cells for Gene Expression
Analysis
2.5×106 cells were transferred to 15 ml falcons and each tube was completed to
900 µl wth 5% FBS supplemented RPMI-1640 media. Stimulants were added in 50
µl 5% FBS supplemented RPMI-1640 media. Tubes were kept in tilted position
with loosened caps until termination of the experiment. Incubation periods for
gene expression studies were 2 and 4 hours.
3.2.3 Spleen Single Cell Suspension Preparation
Mice were sacrificed by cervical dislocation and spleens were removed into 35 mm
petri dish that contains 2 ml ice cold 2% FBS supplemented complete RPMI-1640
with sterile surgical equipment. Then spleens were smashed with back of a
sterile syringe plunger with circular movements in order to obtain single cell
suspension. Media was transferred to 15 ml falcon with sterile pasteur pipette
leaving connective tissue and fat clumps in the petri dish. Then whole cell
suspension is completed to 10 ml and washed twice at 375 g for 5 minutes. After
the final wash step, cells were counted and adjusted to appropriate concentration
for further use.
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3.2.4 Cell Counting by Hemocytometer
After the final wash step, cells were resuspended in 1 ml 5% FBS containing
complete RPMI-1640. Then 20 µl cell suspension were diluted 1:50 with 980 µl
media. Another 15 µl diluted cell suspension is mixed 15 µl Trypan blue (1:1)
and counted with Neubaer cell counting chamber. 16 cells from each corner were
counted and average cell number per 1 mm2 was founded under light microscope.
Each 4×4 cell at corners hold 0.1 mm3 liquid as depth between coverslip and
chamber is 0.1 mm and they have 1 mm2 area. Therefore, total cell number in 1
ml can be calculated by formula;
Average cell number × 2 × 104 × 50(dilution factor) = total cell number.
3.2.5 Cell Counting by Flow Cytometer
After single cell suspension were prepared in 1 ml, 10µl of cell suspension was
added to 990 µl of isotonic solution in 5 ml polystyrene round bottom tubes (BD,
Ref no: 352052). Then particles in 20 µl of resulting suspension were counted in
Accuri C6 Flow Cytometer. Only live and nucleated cells were gated and counted,
apoptotic, dead or non-nucleated blood cells were ignored. Final number was
multiplied with 5.000.
3.2.6 In vitro Splenocyte Stimulation
For stimulation in 96 well cell culture plates with lid (CellStar), 100 µl or 125
µl of 4×106 cells/ml suspension were conveyed to each well(400.000 cells/well
and 500.000 cells/well respectively). Each specific reagent was added in 50 µl
5% FBS supplemented RPMI-1640 media. Finally, each well was completed to
200 µl or 250 µl with 5% FBS supplemented RPMI-1640 media in order to have
2×106 cells/ml. Stimulations were performed in at least duplicate wells and each
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experiment was repeated twice at different times. Supernatants were collected
after 24-36 hours depending on the secretion of specific cytokine to be examined.
For gene expression studies, 2.5×106 cells were transferred to 15 ml falcons and
each tube was completed to 900 µl. Stimulants were added in 50 µl 5% FBS
supplemented RPMI-1640 media. Tubes were kept in tilted position with loosened
caps until termination of the experiment. Incubation periods for gene expression
studies were 2 and 4 hours.
3.2.7 Human Peripheral Blood Mononuclear Cell (PBMC)
Isolation
Blood samples from healthy donors were collected into vacutainer tubes that
contains EDTA as anti-coagulant (BD Vacutainer, purple cap). 15 ml ficoll
(Lymphocyte Separation Medium, Lonza) was placed into 50 ml falcon tube and
22.5 ml. blood from anti-coagulant tubes was gently layered onto the ficoll reagent.
Samples were centrifuged at 500 g for 30 min at room temperature. It is important
to set break off to keep separated layers intact. The buffy coat that PBMCs reside
was collected using sterile pasteur pipette. Cells were washed twice with 50 ml
2% FBS supplemented RPMI-1640 media in a new 50 ml falcon tube (500 g at
RT) to ensure no ficoll reagent was left. At the end of the last wash, pellet was
resuspended in 1 ml 5% FBS supplemented RPMI-1640, samples from same donors
were polled together and cells were counted.
3.2.8 In vitro PBMC stimulation
In vitro PBMC stimulation experiments were done as follows, cells were collected,
isolated and counted as described above (Section 2.2.7). Then, 2.5×105-3×105cells
in 100 µl were layered into wells of 96 well plates (Preferred cell number for each
well was 3×105, however, depending on total cell number and experimental groups,
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2.5×105/well was also used). Different ODN formulations were added in 50 µl and
each well was then completed to 250 µl, yielding 1×106-1.2×106 cells/ml. 220-230
µl of supernatants were collected from each well after 36 hours of incubation.
3.2.9 Liposome Preparation
Phospholipids and cholesterol were prepared as 10 mg/ml or 20 mg/ml stock
solutions in chlorofrom. Stock solutions were stored at −20 ◦C. Various
phospholipids and cholesterol mixed in different ratios in round bottom flasks
to obtain liposomes as shown in Table 3.2 . Chloroform was evaporated using a
rotary evaporator (ILVAC, Germany) in which relatively uniform thin lipid film
was obtained. A brief nitrogen stream was applied onto thin lipid film (30-40 sec)
to remove residual chloroform. Round bottom flasks were sealed with glass caps
in order to prevent oxygen saturation to increase following nitrogen streaming,
presumably minimizing lipid peroxidation. 1 ml of PBS were added for each 20
µmol thin lipid film. If less than 20 µmol lipid was used, up to 10 µmol, PBS
amount was adjusted accordingly, but if lipid film contained less than 10 µmol total
lipid, no less than 500 µl PBS was used. 20-30 glass beads were added to each flask
and lipid film was disrupted by moving flasks rotationally. This step generated
large empty multilamellar vesicles. Resulting milky solution was collected using 1
ml disposable micropipette tip. 100 µl PBS were added again onto glass beads to
ensure most of the liposomes that were entrapped on glass beads were collected. In
order to generate small unilamellar vesicles (SUVs), which arguably most suitable
form of liposomes for encapsulation, liposomes were sonicated 5 times for 30s with
an amplitude of 40% at +4 ◦C and 5 times for 30s with an amplitude of 70%
(VibraCell, SONICS, USA). Liposomes were kept on ice for 10 seconds in between
sonications to prevent excessive heating. For 20 µmol lipid, 1 mg ODN was added
to SUVs. If there were less than 20 µmol or SUVs were aliquoted, ODN amount was
adjusted properly (1mg ODN/20 µmol lipid). ODN-SUV mixture was then snap
frozen in liquid nitrogen and lyophilized (Benchtop K, Virtis, USA). Dehydrated
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ODN-liposome mixtures appeared as powders after this step and encapsulation
was achieved during controlled rehydration step, as previously reported (referans).
Briefly, if the sample volume was more than 300 µl, 1:10 volume of DNase RNase
free ddH2O of the final volume prior to lyophilization was added. (e.i. 50 µl DNase
RNase free ddH2O was added for 500 µl liposome-ODN mixture). If it was less
than 300 µl, 30 µl DNase RNase free ddH2O was added onto powder and vortexed
for 15 s every 5 min for 5 times at RT. Same amount of PBS was added to mixture
and vortexed for a few seconds. Then final volume was adjusted to yield 1µg/µl
ODN. Liposome preperations were stored at +4 ◦C until use.
Table 3.2: Lipid composition and molar ratios for different liposomes, taken from
another study by Gursel et al. [115]
Liposome Type Liposome Composition (molar ratio)
Neutral PC:Chol (1:1)
Anionic PC:DOPE:PS (1:0.5:0.25)
Cationic DC-Chol:PC:DOPE (4:6:0.06)
Stealth Chol:DOPE:PEG-PE (4:6:0.06)
Cationic-Stealth (SSCL) DC-Chol:DOPE:PEG-PE (4:6:0.06)
PC, phosphatidylcholine; Chol, cholesterol;
DOPE, dioleylphosphatidylethanolamine; PS, phosphatidylserine;
DC-Chol, dimethylaminoethanecarbamol-cholesterol;
PEG-PE, polyethylene glycol-phosphatidylethanolamine
3.2.10 Enzyme Linked ImmunoSorbent Assay (ELISA)
3.2.10.1 Cytokine ELISA
When desired time point was reached, 96 well plates were spun at 400g for 5
minutes. Supernatants (170-220 µl) were collected into new 96 well plates and
either immediately used or stored at -20 until another use. PolySorb Nunc
Immuno Plates were coated with monoclonal antibodies against mouse or human
cytokines (50 µl/well) and incubated for 4 hours at RT or for ON at +4 ◦C. As
each antibody against different cytokines optimized at different concentrations,
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working concentrations for coating antibodies were given in Table 3.3. Coating
antibody solution was discarded and wells were blocked with 200 µl 5% w/v
BSA-1X PBS 0.025% Tween-20 at RT for 2 hours. Plates were washed with
PBS-Tween 20 (0.05% Tween) 5 times. PBS-Tween 20 was kept in wells in
between and plates were rinsed with ddH2O 3 times. Plates were dried by tapping.
Washing was repeated after subsequent steps. 50 µl supernatants and recombinant
cytokine standards were added into the wells. Starting concentrations for cytokine
standards (duplicate) were given in Table 3.4. Standards were serially diluted 2
fold with 50 µl 1X PBS 7 or 11 times. Two wells were left with 50 µl 1X PBS for
blank measurement. Samples and standards were incubated ON at +4 ◦C. Plates
were washed and Biotin conjugated antibodies against human and mouse cytokines
that were diluted (1:1000) in %5 v/v FBS-1X PBS %0.025 Tween-20 and 50 µl
added into each well and incubated at RT for 3 hours. During this incubation,
Streptavidin-Alkaline Phosphatase (SA-AKP) was diluted (1:3000) in the same
buffer as biotinylated antibodies, since SA-AKP works best when prepared at least
1-2 hours beforehand. After washing of plates, 50 µl diluted SA-AKP were added
to each well. After 1 hours of incubation at RT, Plates were washed and PNPP
substrate was added (50 µl/well). For one plate, one PNPP tablet was dissolved
in 4 ml ddH2O and 1 ml 5X buffer was added afterwards. Until 2X serially diluted
recombinant proteins generate an S-shape standard curve, ODs at 405 nm were
read after each 30 min intervals with an automated plate reader (BioLabs).
Table 3.3: Working concentrations for coating antibodies
Anti mouse IL6 2 µg/ml
Anti mouse IL12 4 µg/ml
Anti mouse IL10 7.5 µg/ml
Anti human IL6 2 µg/ml
Anti human TNFα 3 µg/ml
Anti human IFNγ 5 µg/ml
Anti human IFNα 5 µg/ml
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Table 3.4: Starting concentrations for recombinant cytokines
Recombinant mouse IL6 1000 ng/ml
Recombinant mouse IL12 500 ng/ml
Recombinant mouse IL10 50 ng/ml
Recombinant human IL6 1000 ng/ml
Recombinant human TNFα 1000 ng/ml
Recombinant human IFNα 250 ng/ml
3.2.10.2 IgG ELISA
IgG ELISA was very similar to cytokine ELISA except a few changes. Washing
procedure was identical and incubation times were very similar. PolySorb Nunc
96 well plates were coated with 50 µl 5 µg/ml soluble part of total textith. felis
cell extract, which was a kind gift of Ayca Sayı Yazgan (ITU) and incubated ON
at +4 ◦C. Wells were blocked with same blocking buffer for 2 hours at RT as
cytokine ELISA and washed. Sera from mice was diluted as follows in different
96 well U bottom plates; First row was prepared by mixing 40 µl serum with 240
µl 1X PBS in order to obtain 1/7 titration. 210 µl 1X PBS were added to rows
beneath. 70 µl from the rows above were added to rows below, in which samples
were titrated 1:4 at each row. Samples were diluted one time 1:7 and seven times
1:4. 50 µl of serum titrates were added to each well and incubated ON at +4 ◦C.
Plates were washed. Antibodies that were raised against heavy chain of mouse
antibody subclasses or against total IgG directly linked to alkaline phosphatase
(AKP). Antibodies against total IgG, IgG2a and IgG1 were diluted 1:2000 in 5%
v/v FBS-1X PBS 0.025% Tween-20 whereas antibodies against IgA were diluted
1:1000. 50 µl diluted AKP-linked antibody were added to wells and incubated at
RT for 2-3 hours. Plates were washed again and PNPP substrate was added. OD
measurements at 405 nm were taken in every 30 minutes after PNPP addition.
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3.2.11 Total RNA Isolation
As stimulations for gene expression studies were done in 15 ml falcon tubes,
samples were directly centrifuged at 500 g for 5 minutes. All centrifugations
were done at +4 ◦C and all steps were completed on ice during RNA isolation.
Supernatants were discarded and pellet was resuspended with ice cold PBS,
centrifuged again at 500 g for 5 minutes. Supernatant was again discarded and 1
ml Trizol reagent (Invitrogen) directly added onto pellet. Mixate was homogenized
by repetitive pipetting and transfered to 1.5 ml eppendorf tube. In order to reach
critical 5:1 phenol chloroform ratio in phenol-chloroform extraction method, 200 µl
of chloroform (Sigma) added to 1 ml homogenate and tubes were vigorously shaken
for 10-15 seconds. Samples were incubated 3 minutes at RT before centrifugation at
16.000 g for 17 minutes. Approximately 450-500 µl of clear upper phase (aqueous
phase) was transferred to new 1.5 ml eppendorf tubes and 500 µl isopropanol
was added and tubes were gently inverted to ensure proper mixation, followed by
incubation for 10 minutes at RT. Samples were spun at 16000 g for 15 minutes.
Supernatants was discarded and 1 ml 75% ethanol was added. At this points, in
order to remove trace amounts of isopropanol, samples were vortexed just long
enough to move pellet. Samples were spun at 6000g for 8 minutes and gently
washed with >99.9% ethanol. Samples were centrifuged once more at 6000g for
8 minutes, supernatant was discarded, and samples were dried in a petri dish in
tilted position. Dried pellets were dissolved in 20 µl DNAse RNAse free water.
RNA quality and quantity was assessed by OD measurements at 260 and 280
nm, which were obtained by NanoDrop ND1000 spectrophotometer. Isolated
RNA samples were expected to have a 260/280 ratio between 1.8-2.0, which is an
indicator minimal DNA, protein and organic solvent contamination. For samples
that did not have proper 260/280 ratio, ethanol washing steps were repeated, until
acceptable values were reached.
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3.2.12 cDNA Synthesis
cDNA was synthesized from total RNA with ProtoScript First Strand cDNA
Synthesis Kit (NEB) according to manufacturers instructions. Briefly, 1 µg of
total RNA was mixed with 100 ng oligo(dT)15 primer (1 µl) and each sample was
completed to 8 µl with DNAse RNAse free water. After a pre-denaturation step
(5 min at +65 ◦C),10 µl RT Buffer (including dNTP mix and 10 mM MgCL2) and
2 µl M-MuLV RNase H+ reverse transcriptase (includes RNase inhibitor) were
added to tubes. samples were spun down quickly. Reaction conditions were as
follows; 1 hour at +42 ◦C, 5 minutes at +85 ◦C. cDNAs were stored at −20 ◦C for
further use.
3.2.13 PCR
Primers specific to mouse genes were designed NCBI′s primer designing tool
(Primer BLAST) which uses Primer3 for primer designing and NCBIs database
along with BLAST and global alignment algorithms to screen primer pairs
availability. All primers were further analyzed via online UCSC in Silico PCR tool
to test primer pairs with different databases and algorithms. Detailed information
on mouse primers and their reaction conditions were given in Table 3.5 and
Table 3.6 respectively.
PCR reaction mixtures were prepared with Quick-Load Taq 2X Master Mix
(NEB) which loading dye was included in MAster Mix directly. Final volume
was 25 µl for each primer pair which contained 12.5 µl Master Mix, 1.5 µl cDNA
solution, 1 µl from forward primer and 1 µl from reverse primer and 9 µl ddH2O.
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Table 3.5: Designed mouse primers and amplicon sizes
Primer Sequence Amplicon Size
mIL1β Forward 5′-GCTGCTTCCAAACCTTTGAC-3′ 431 bp
Reverse 5′-GGCCACAGGTATTTTGTCGT-3′
mIL6 Forward 5′-TGGAAATGAGAAAAGAGTTGTGC -3′ 120 bp
Reverse 5′-CAGTTTGGTAGCATCCATCATT -3′
mMIP1α Forward 5′-ACCATGACACTCTGCAACCA-3′ 238 bp
Reverse 5′-AGGCATTCAGTTCCAGGTCA-3′
mIP10 Forward 5′-GCCGTCATTTTCTGCCTCAT-3′ 127 bp
Reverse 5′-GCTTCCCTATGGCCCTCATT-3′
mTLR9 Forward 5′-AGTGTCACTTCCTCAATTCTCT -3′ 118 bp
Reverse 5′-TTCGACGGAGAACCATGTTG -3′
mGAPDH Forward 5′-AGCTCATTTCCTGGTATGACA -3′ 128 bp
Reverse 5′-CTCTCTTGCTCAGTGTCCTT -3′
Table 3.6: PCR conditions for mouse primers
Gene Names
PCR Steps (Temp; Time) mIL6, mTLR9 & mGAPDH mIL1β,mMIP1α & mIP10
Initial Denaturation 94 ◦C; 5′ 94 ◦C; 5′
Denaturation 94 ◦C; 30′′ 94 ◦C; 30′′
Annealing 60 ◦C; 30′′ 55 ◦C; 30′′
Extension 72 ◦C; 40′′ 72 ◦C; 40′′
Cycle # 30 35
Final Extension 72 ◦C; 5′ 72 ◦C; 5′
3.2.14 Agarose Gel Electrophoresis
Agarose gel was prepared with 2% (w/v) agarose in 150 ml 1X TAE buffer.
Ethidium bromide was added as 1 µg/ml. Lanes were loaded with 10 µl PCR
product. 3 µl 50-500 bp or 100-1000 bp DNA ladders (BioLabs, USA) were used
as markers. Gels were ran at 110V for 50-55 minutes and visualized under UV
transilluminator (Vilber Lourmat, France).
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3.2.15 Immunization Protocol
Five adult female C57/BL6 mice per group were tail bled prior to immunization
(d=-1) and one day later (d=0) they were injected with liposomes that
co-encapsulated 15 µg soluble whole . . . H. felis extract and 15 µg ODN
subcutaneously. Two weeks later, booster injection was done (d=14). Just one
day before booster injection (d=13), animals were tail bled and sera were collected.
Two weeks (w=4) and six weeks (w=8) after booster injection, animals were tail
bled and sera were collected again. Timeline for immunization protocol was given
in Figure 3.1
Figure 3.1: Timeline for immunization of mice with CpG and H. felis cell extract
or liposomes co-encapsulating CpG and H. felis cell extract
3.2.16 Sera Collection from Immunized Mice
Mice were bled prior to immunization, one day before booster injection, 2 weeks
after booster injection and six weeks after booster injection. Blood was obtained
from tail veins of animals and collected to round bottom borosilicate glass test
tubes. Blood samples were incubated at +37 ◦C for 2 hours. After incubation,
clot and remaining liquid part can be separated. Liquid part from each sample
was collected to 1.5 ml eppendorf tubes, centrifuged at 6000 g for 5 min at RT and
cell and cell debris free supernatants were collected to 96 well plates and samples
were stored −20 ◦C until use.
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3.2.17 Maintenance of Animals
For immunization, only adult female BALB/c mice (8-12 weeks old) were used.
Adult female or male BALB/c or C57/BL6 mice were used for isolation of spleen
cells. Animals were housed in the animal holding facility of the Bilkent University
Department of Molecular Biology and Genetics. Animals were kept in monitored
and controlled environment at +22± 2 ◦C with 12 hour light 12 hour dark cycles.
Animals had ad libitum access to food and water. All experimental procedures have
been approved by the animal ethical committee of Bilkent University (Bil-AEC)
3.2.18 Statistical Analyses
Two tailed Student’s t test was used to understand statistical difference between
treatment groups. p<0.01 was accepted as statistically significant difference.
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Chapter 4
Results
4.1 Effects of Liposomes Encapsulating D-ODN
and K-ODN on RAW 264.7 Gene Expression
First, we determined to compare the immunostimulatory effects of different classes
of free form of CpG ODNs to that of liposomes encapsulating CpG ODNs
on specific gene message transcript upregulations of several pro-inflammatory
cytokines (IL6 and IL1β), chemokines (MIP1α and IP10) and TLR9 using RAW
264.7 cells. K and D type CpG ODNs, namely K3 and D35, respectively along with
their control sequences K3-flip and D35-flip were used during these comparison
studies. Based on our previous experience, K3 was encapsulated within neutral
liposomes (NL) and D35 was encapsulated within anionic liposomes (AL) ([113]).
Cells were stimulated with different treatments for 2 or 4 hours. After cells were
pelleted and total RNA was purified, specific gene transcripts were studied by
RT-PCR. Of note, PGN and LPS were used as positive controls throughout these
analyses. Figure 4.1 shows agarose gel electrophoresis images of analyzed gene
transcripts following RT-PCR.
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Pro-inflammatory cytokines IL1β and IL6 mRNA levels were not visible
without any stimulation. Furthermore, neither K3 nor neutral liposomes
containing K3 could improve the upregulation of these genes. Moreover, D35
alone also failed to induce any IL1B and IL6 expression. However, D35 in anionic
liposomes not only induced higher expression levels of both IL6 and IL1β, it showed
much longer lasting activation effect, since LPS mediated upregulation subsided
by 4h compared to 2 h stimulation AL-D35 band intensities remained unchanged.
Chemokines (MIP1α and IP10 have a basal level of expression. Similar to
cytokine expression, neither K3 nor NL-K3 could increase further than the basal
level. In fact, it seems that NL induced a slight decrease for both chemokines.
Similar to IL6 and IL1β case, free D35 also did not increase any chemokine
expression. AL containing D35, however, increased expression of MIP1α and IP10
at 2 hours. Unlike cytokines IL1β and IL6, chemokine expression levels at the end
of 4 hours in vitro stimulation did not subside. BothMIP1α and IP10 expressions
continued to increase at 4 hours when cells were stimulated with AL-D35.
TLR9 is a receptor evolved to sense unmethylated CpG motifs. When we
checked whether free or liposomal CpG ODNs could induce any increase in the
expression level of this receptor whereas only D35 within liposomal formulation,
led to an increase of TLR9 expression.
When taken together these results suggested that Anionic Liposomes loaded
with D35 CpG ODN induces much stronger and persisting cytokine/chemokine
upregulation than other treatments.
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Figure 4.1: Gel photomicrographs of several gene products following RT-PCR
obtained from total RNA of RAW 264.7 cells following stimulation with free K3
or within neutral liposome (NL), free D35, or within anionic liposomes (NL) along
with their control sequences. PGN (2.5 g/ml) and LPS (1.0 g/ml) were used as
positive controls.
4.2 In Vitro Stimulation of Splenocytes with
Liposomal CpG ODN
One of the major aims of this thesis was to develop a vaccine formulation that
could be effective against Helicobacter infections and furhermore could be tested
in a mice model. To this end, candidate ODNs were tested in an in vitro assay
before mice experiemnts were initiated. Splenocytes were stimulated either with
liposomes that co-encapsulated K23 and K3 (1:1 w/w or 5:3 molar ratio) or
1466 and D3CG (1:1 w/w). Co-encapsulation is a powerful feature enabled by
dehydration-rehydration method for preparing cargo loaded liposomes. While K23
and K3 had complete phosphorothioated backbone (i.e. PS), 1466 and D3CG had
mix-backbone (PS/PO/PS) In our in vitro assays we intended to co-encapsulate
these ODN pairs within five different type of liposomes. These formulations then
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diluted serially by 3 fold to determine the lowest active dose in vitro. Cells were
following 36 hours of in vitro incubation were harvested and supernatants were
assessed for IL6, IL12 and IL10 productions by ELISA.
Free or liposomal formulations of K3 and K23 or their free counterparts
stimulated much higher IL6 secretion than 1466 Acore MB and D3CG MB CpG
ODNs (Figure 4.2 and Figure 4.3). This was an expected finding, because K23
and K3 were both members of K type ODN and these ODNs are generally known
to be strong IL6 inducers. D3CG is a D type ODN and 1466 is modified to become
a D-like ODN too. Of note, D type ODNs are relatively weak IL6 inducers.
As seen in Figure 4.2 different mixtures of K23 and K3 (only at higher doses)
did not perform better when they were coencapsulated into liposomes than when
they were used alone or together. As expected, at suboptimal doses, such as 9
fold or 27 fold dilution, K23 and K3 mixture in liposomes were much more potent
(Figure 4.2). Interestingly, K23 alone showed the greatest stimulation almost at
all dilutions in vitro. Still, we focused on K23 and K3 mixture and their liposomal
counterparts as it is vital to use several sequences together as a mixture in vivo or in
clinical trials, since individuals show different response to different sequences and
a mixture yields the best response ([114]). Among five different liposome types,
cationic liposomes at high doses were similar to that of free ODN responses. As it
was titrated down, they displayed more potent immunostimulatory effects, at low
doses. This might be due to toxicity of cationic lipids and when dose was reduced,
toxicity decreased and cationic liposomes induced IL6 secretion comparable to
other liposome types. In general, at low doses all liposome formulations stimulated
splenocytes to secrete IL6 better than free K23 and K3 mixture.
In addition to IL6 secretion, IL12 production from splenocytes followed by
stimulation with free or liposomal CpG ODN was assessed. Both K23/K3 mixture
and 1466/D3CG mixtures led to similar amounts of IL12 when ODNs were at high
doses (Figure 4.4 and Figure 4.5). For IL6, K23/K3 mixture had an obvious upper
hand. Consistent with IL6, IL12 levels were higher at low doses when liposomal
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formulations were used to stimulate spleen cells. Notably, at the lowest dose,
anionic liposomes co-encapsulationg K23 and K3 mixtures induced pronounced
IL12 secretion (Figure 4.4). Importantly, IL12 levels remained relatively stable
with regard to serial dilutions of the ODN mixture. It is important to note that at
low doses, mixing K23 and K3 made a positive contribution to immunostimulatory
capacity of the ODNs supporting the view that a CpG ODN cocktail instead
of using one specific type of CpG ODN sequence improves in vivo performance
and breadth of activation. Unlike K23 and K3 stimulation, we observed a dose-
dependent reduction in the levels of IL12 after stimulation with 1466 and D3CG
mixture (Figure 4.5). Of note, cationic lipid containing formulations performed
better for IL12 induction. Consistently in our hands, these formulations were the
most potent liposomal formulations for IL6 secretion.
Finally, IL10 is an immunomodulatory cytokine, supporting Treg development.
When we checked the IL10 production levels of different ODN mixtures, 1466
Acore MB and D3CG MB did not induce any detectable IL10 secretion. K23 and
K3 induced IL10 secretion, however, there was no significant difference between
liposomal formulations and free CpGs (Figure 4.6).
All these activities were CpG motif dependent, since control ODN or empty
liposomes were inactive. Of note, amount of lipids were even higher than the lipids
administered along with the highest CpG ODN formulations, but there was no
notable difference from untreated spleen cells after stimulation with free liposomes.
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Figure 4.2: Dose dependent IL6 secretion profiles of different liposome formulations
co-encapsulating K23, and K3. Spleen cells (2X106 cells/ml) were treated with
different doses of liposome formulations in culture. Starting doses corresponded
to 1 µmol/ml ODN and diluted 3 fold at each subsequent steps, for four times.
36h later supernatants were collected and IL6 levels were detected by Cytokine
ELISA. p<0.01 for liposomal vs free K23 + K3 mixture at 1/9 and 1/27 dilutions
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Figure 4.3: Dose dependent IL6 secretion profiles of different liposome formulations
co-encapsulating 1466 Acore MB, and D3CG MB. Spleen cells (2X106 cells/ml)
were treated with different doses of liposome formulations in culture. Starting
doses corresponded to 1 µmol/ml ODN and diluted 3 fold at each subsequent
steps, for four times. 36h later supernatants were collected and IL6 levels were
detected by Cytokine ELISA. p<0.01 for SSCL and cationic liposomal vs. free
1466 + D3CG mixture at 1/9 dilution
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Figure 4.4: Dose dependent IL12 secretion profiles of different liposome
formulations co-encapsulating K23, and K3. Spleen cells (2X106 cells/ml) were
treated with different doses of liposome formulations in culture. Starting doses
corresponded to 1 µmol/ml ODN and diluted 3 fold at each subsequent steps, for
four times. 36h later supernatants were collected and IL6 levels were detected by
Cytokine ELISA.
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Figure 4.5: Dose dependent IL12 secretion profiles of different liposome
formulations co-encapsulating 1466 Acore MB, and D3CG MB. Spleen cells (2X106
cells/ml) were treated with different doses of liposome formulations in culture.
Starting doses corresponded to 1 µmol/ml ODN and diluted 3 fold at each
subsequent steps, for four times. 36h later supernatants were collected and IL6
levels were detected by Cytokine ELISA. p<0.01 for SSCL and cationic liposomal
vs. free 1466 + D3CG mixture at 1/3, 1/9 and 1/27 dilution
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Figure 4.6: Dose dependent IL110 secretion profiles of different liposome
formulations co-encapsulating K23, and K3. Spleen cells (2X106 cells/ml) were
treated with different doses of liposome formulations in culture. Starting doses
corresponded to 1 µmol/ml ODN and diluted 3 fold at each subsequent steps, for
four times. 36h later supernatants were collected and IL6 levels were detected by
Cytokine ELISA.
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4.3 Immunization with Liposomes Co-Encapsulate
CpG ODN and H. felis Total Cell Extract
After in vitro studies, the most potent candidates were selected for H. felis
immunization in mice. Anionic liposomes for K23 and K3 co-encapsulation and
liposomes with cationic lipids for 1466 and D3CG co-encapsulation were arguably
the most prominent formulations. Although cationic liposomes were as prominent
for 1466 and D3CG, we thought that SSCL that contain PEG along with cationic
lipid were also suitable for immunization study. Finally, we also included 1555 in
cationic liposomes for H. felis immunization, since this formula was shown to be
a strong immune stimulant in another study [113].
6-8 weeks old female BALB/c mice were immunized on day 0 and day 14 with
H. felis total cell extract along with CpG ODN or their liposome encapsulated
forms. One day before booster injection (d=13), two weeks after booster injection
and 6 weeks after booster injection mice were tail bled, sera were collected, titrated
and IgG, IgG1 and IgG2a levels were analyzed by ELISA. IgG2a/IgG1 ratio was
calculated to determine whether cell mediated immunity or humoral immunity was
the outcome after immunization.
Many conventional vaccines require a booster injection after primary injection
to promote sufficient immune protection. This is also very important in mice
vaccination studies. However, we decided to include comparison of IgG levels
after the primary injection, because we postulated that H. felis extract naturally
contains many immunomodulatory molecules and they might contribute along with
CpG ODN to boost a robust anti-H.felis immunity even after single vaccination.
As mentioned above, H. felis is a gram negative bacteria and mammalian immune
system has more than one mechanism to recognize components of gram negative
bacteria. This might have been also a drawback; since injection of total cell
extract could mask the effect of co-encapsulation of H. felis antigen along with
CpG adjuvants within liposomes.
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Bleeding two weeks after primary injection revealed that H. felis total cell
extract is sufficient to provoke immune system to produce IgG against H. felis
antigen (Figure 4.7). In fact, much to our surprise at first hand, two of PBS
injected mice also had high levels of IgG (Figure 4.7, also see Appendix for IgG2a
and IgG1 graphs for 1st bleed). Under certain circumstances, however, this is not
as surprising as it first seems. Our facilities are not pathogen free and it is likely
that those animals have encountered gram negative bacteria before.
Regarding free CpG ODNs and their liposomal encapsulated forms in terms of
total IgG production, there were not essential difference between them, but there
were slight improvement of free CpGs over liposomal formulations (Figure 4.7.A).
This is also true for IgG2a subtype (Figure 4.7.B). In terms of IgG1 subtype, no
conclusive inference can be done as IgG1 readings were not proportional to dilution,
which probably means they were below proper detection limit (Figure 4.7.C)
After the booster injection, liposomal formulations were still not performing
better than free CpGs in terms of total IgG. Free 1466 Acore MB and 1555 were
better at the selected dilution (1/7168) and only Anionic K23&K3 had a slight
advantage over free K23&K3 (Figure 4.8.A). IgG subclasses IgG1 and IgG2a,
however, gave mixed results. Liposomal 1466 indeed induced more IgG2a secretion
than its free form, whereas other formulations induced more IgG2a secretion when
they were injected in free forms (Figure 4.8.B). IgG1 secretion was more for Anionic
K23&K3 and SSCL 1466. Liposomal 1555 and free 1555 induced approximately
the same levels of IgG1. (Figure 4.8.C).
IgG levels for each mouse and each group after second bleeding were as expected
gave higher titers than the first bleeding (Figure 4.8). IgG levels of animals that
were immunized with H. felis cell extract alone also had high levels of IgG in their
sera (Figure 4.8), even higher than some liposomal groups (i.e. Cationic 1555 ).
Nevertheless, CpG groups had still more effective for IgG2a and IgG1.
Third bleed was important to judge the persistance of antibody titers agains
H.felis. As this bleeding was 6 weeks after the last injection, we thought that
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IgG levels of mice that were injected with H. felis cell extract alone would start to
subside down to normal levels. We also expected that liposomal CpG formulations
would have induced higher IgG than free CpGs since they would affect more
immune cells due to co-encapsulation and relatively slow serum clearance. Our
initial assumptions were partially true. Total IgG levels of mice immunized with
cell extract alone were lower, but CpG injected groups were also lower (Figure 4.9).
Besides, liposomal CpGs were again not better than free CpGs (Figure 4.9.A).
However, IgG2a and IgG1 showed stronger anti H. felis titers. Anionic K23&K3
clearly induced more IgG2a and IgG1 than those of free CpG and H. felis cell
extract alone (Figure 4.9.B and Figure 4.9.C). SSCL 1466 and cationic 1555 also
caused more IgG1 secretion (Figure 4.9.C).
We finally compared IgG2a and IgG1 levels of immunized mice. IgG2a/IgG1
ratio is used to determine whether antibody response led to a Th1-biased (cell
mediated) or humoral immune response. If the ratio is higher than 1, it means
Th1 response is dominant and if it is smaller than 1 antibody mediated response is
dominant. Among treatment groups, only free K23&K3 were able to have a ratio
of IgG2a/IgG1 higher than 1 (Figure 4.10), which was lost 4 weeks later. It was
considerable that free CpG groups have all higher ratio than liposomal groups, that
quickly turned just the opposite at the end of 6 weeks post booster injection. It is
tempting to speculate that liposomal groups caused more stable immune reaction
than free CpG groups, however, we did not have means to test this possibility.
These animals are still under investigation and H.felis challenge will be done to
these mice at the end 10 weeks. The time frame of this thesis unfortunately goes
beyond these assays.
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Figure 4.7: Comparison of IgG levels of immunized mice against H. felis 2 weeks after 1st
injection. Mice (5 mice/group) were immunized against H. felis with CpG ODN and H. felis
total cell extract or liposomes that co-encapsulate CpG ODN and H. felis total cell extract.
IgG levels were detected with IgG ELISA. A. Total IgG levels. B. IgG2a levels. C. IgG1 levels.
For individual responses and means, see Figures A.1- A.4.
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Figure 4.8: Comparison of IgG levels of immunized mice against H. felis 2 weeks after booster
injection. Mice (5 mice/group) were immunized against H. felis with CpG ODN and H. felis
total cell extract or liposomes that co-encapsulate CpG ODN and H. felis total cell extract.
IgG levels were detected with IgG ELISA. A. Total IgG levels. B. IgG2a levels. C. IgG1 levels.
For individual responses and means, see Figures A.7- A.10.
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Figure 4.9: Comparison of IgG levels of immunized mice against H. felis 6 weeks after booster
injection. Mice (5 mice/group) were immunized against H. felis with CpG ODN and H. felis
total cell extract or liposomes that co-encapsulate CpG ODN and H. felis total cell extract.
IgG levels were detected with IgG ELISA. A. Total IgG levels. B. IgG2a levels. C. IgG1 levels.
For individual responses and means, see Figures A.13- A.16.
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Figure 4.10: Persistence of anti-H.felis responses among different treatment
groups.
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4.4 Simultaneous Stimulation of PBMCs with
liposomes encapsulating D35 or K3
In humans, K type ODNs and D type ODNs have different immune stimulatory
properties. K type ODN stimulates TNFα secretion from pDCs, whereas D type
ODN induces IFNα secretion. K type ODN, therefore initiates a pro-inflammatory
cascade against invading pathogens (mostly effective against bacterial infections),
D type ODN, however, leads to mainly antiviral immune response via type I
interferon signaling. A good protective reagent would have ability to induce
both type of immune reactions against diverse range of pathogens. Unfortunately,
simultaneous administration of K and D type ODNs is not an option in their
free forms, as mentioned in Section 1.3.4, this is mainly due to counter action
of these ODNs on immune cells. When K-ODN is internalized by pDC, due to
accumlation of K-ODN in late endosomes, it leads to maturation of pDCs along
with TNFα secretion, therby D-ODN effect is abolished. Several groups have tried
to develop new CpG ODN classes (such as C-type ODNs, or P-Type ODNs), but
none of those efforts successfully recapitulated D ODN-specific effects (i.e. these
new ODN classes are still more close K-type ODN activity).
We tried to overcome this problem by encapsulating D and K type ODN within
different liposomes and tried to analyze these different liposomes loaded with K
or D type ODNs in a synergistic fashion. In a preliminary experiment, we aimed
to identify candidate liposome types loaded with different ODNS. We asked the
question whether there are synergistic liposome formulations. Here the idea was to
identify different liposome combinations where D and K ODNs does not cancel each
other‘s activity when loaded within liposomes. PBMCs were isolated from blood of
two healthy subjects and stimulated in culture simultaneously with K and D type
ODNs (free or liposome encapsulated forms). We tested all five type of liposomes
for K type ODN K3 encapsulation and neutral and anionic type liposomes for
D type ODN D35 encapsulation. We also used two different concentrations
of CpG ODNs (0.3 uM and 1.0 uM) to mix optimum and sub-optimum ODN
54
concentrations as this might have been the key for ODN synergism.
Figure 4.11 shows IL6 profile of PBMCs that were stimulated with K3 and/or
D35 encapsulated into different liposomes. IL6 secretion did not show noteworthy
additive or synergistic effect of K3 and D35 when PBMCs were treated with high
doses of K3 (1.0 uM K3). We were able to see higher induction of IL6 secretion
when 0.3 uM K3 was mixed with 0.3 uM or 1.0 uM D35 than either D35 or K3.
TNFα secretion was also increased positively by simultaneous administration of
K3 and D35 at lower doses, albeit there were some additive effects of K3 and
D35 at higher doses (Figure 4.12). Although both K3 and D35 were reported as
good immune stimulants for PBMCs, we did not see any IL6 secretion when CpG
ODNs were used without liposomes. PBMCs from subject #1 (S1 hereafter) were
also not stimulated by free CpG ODNs to secrete TNFα. Only S2 had very little
TNFα secretion. This situation is a proof that liposomes can boost the effect of
CpG ODNs. It is also important to note that empty liposomes did not induce
any cytokine or interferon induction indicating that the activation is CpG motif
dependent (data not shown).
IFNγ production by K3 and D35 somewhat affected different from IL6 and
TNFα. D35 is a natural inducer of IFNγ. Yet rates of IFNγ were not detectable
even when liposomal D35 was used (Figure 4.13). Low dose K3 also did not
produced any interferon. However, when 1 uM K3 in liposomes was used, PBMCs
started to secrete detectable levels of IFNγ. Among different liposomes, stealth
liposomes encapsulated K3 were the most successful type. Interestingly, when only
liposomal K3 was used, IFNγ production was superior. Only SSCL liposomes
encapsulating K3 showed a synergism with liposomal D35. This effect was subject
specific. Only in S2, IFNγ production was detectable, unfortuantley in S1 it
was completely absent. This was a good demonstration of discrepancy in human
responses. Nevertheless, it was clear that 1.0 µM K3 in high doses were able to
induce IFNγ, when delivered in specific liposome formulation. This is an indication
of the alteration of the subcellular distribution of K3 when given in liposomes. It
was also worth mentioning that in our hands, D35 mediated cytokine production
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is dose independent.
Figure 4.14 shows IFNα induction ability of the PBMCs. This figure contains
only groups that were treated with cationic K3 and free or liposomal D35 since
regardless of liposome type, when free or liposomal encapsulated K3 was used
along with D35, D35 lost much of its IFNα induction activity. When PBMCs
were treated with cationic liposomes that encapsulate K3 along with liposomal
D35 cells were able to secrete IFNα. Alone D35 at high dose induced higher IFNα
in S2 but not in S1. K3 completely abolished this effect in S2. Both PBMCs from
two subjects secreted high amounts of IFNα when neutral or anionic liposomes
containing D35 were used. When taken together, the cytokine profiles of PBMCs
from two subjects suggested that suboptimal doses (0.3 uM) of K and D type
ODNs in liposomes are indeed important for synergistic stimulation of immune
cells. This is probably due to alteration of subcellular fate of K3 when delivered
in liposomes thus cancelling their competitive induction pathways.
We, therefore, planned a follow up study to investigate in depth the beneficial
effect of combining two types of ODNs within liposomes. For this, we have chosen
a single K3 dose (0.3 uM) in liposomes, along with either 0.3 or 1.0 uM D35.
Based on the preliminary study only cationic lipid containing liposomes (cationic
and SSCL) were chosen for K3. K3 in those liposomes did not exhibit considerable
disparity for cytokines IL6. TNFα and IFNγ was perniciously affected by those
liposomes. In fact, IFNγ secretion was almost none when cationic liposomes
encapsulating K3 were given to PBMCs, however, other liposomes has done the
same thing for IFNα. Consequently, cationic liposomes and SSCL were our prime
candidates for K3 encapsulation. We deduced that neutral and anionic liposomes
were not enough for D35 encapsulation, henceforth we included stealth liposomes
for the next study.
Figure 4.15 and 4.16 shows IL6 and TNFα secretion following stimulation
of PBMCs from four different healthy subjects with simultaneous treatment of
liposomes encapsulating K3 and D35, respectively. Among liposomal K3 groups,
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SSCL performed better for those cytokines in this study. Although exact cytokine
amounts differ between patients, the general trend was strikingly the same.
SSCL-K3 consistently stimulated IL6 and TNFα secretion. This effect of SSCL-K3
was synergized with Anionic-D35 and partially abolished with Stealth-D35 or
Neutral-D35. Neither free K3 nor free D35 reproduced this effect when IL6 and
TNFα were considered.
Unfortunately, only one subject′s PBMCs secreted IFNγ (Figure 4.17).
SSCL-K3 was again the most successful one. IFNα secretion profile of subjects
exhibited intriguing discrepancy (Figure 4.18). Free D35 induced IFNα secretion in
a dose dependent manner, which was lost when K3 added as the second stimulant.
For two out of four subject (S1 and S4), as such Cationic-K3 but not SSCL-K3
or liposomal D35 formulations stimulated IFNa secretion, whereas for one subject
only the liposomal D35 induced IFNα secretion. (S1). For the remaining subject
(S2), liposomal D35 and Cationic K3 were both active, although liposomal D35
alone induced higher IFNα level. Furthermore, the groups that cationic liposomes
synergized with D35 encapsulating liposomes were different.
In conclusion, it was apparent that when K and D type CpG ODNs were
encapsulated within different liposomes and administered simultaneously, it was
possible to induce secretion of different cytokines and interferons that were
normally not likely to be secreted in other forms. However, we still lack conclusive
evidence for which types of liposomes have superiority over others to consistently
and reproducibly activate both K and D ODN specific signaling pathways.
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Figure 4.11: Dose and Liposome type dependent IL6 production by K and D type
CpG ODNs from human PBMCs
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Figure 4.12: Dose and Liposome type dependent TNFα production by K and D
type CpG ODNs from human PBMCs
59
Figure 4.13: Dose and Liposome type dependent IFNγ production by K and D
type CpG ODNs from human PBMCs
60
Figure 4.14: Dose and Liposome type dependent IFNα production by K and D
type CpG ODNs from human PBMCs
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Figure 4.15: IL6 production after simultaneous administration of liposomal K and
D to human PBMC 62
Figure 4.16: TNFα production after simultaneous administration of liposomal K
and D to human PBMC
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Figure 4.17: IFNγ production after simultaneous administration of liposomal K
and D to human PBMC
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Figure 4.18: IFNα production after simultaneous administration of liposomal K
and D to human PBMC
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Chapter 5
Discussion
In this thesis, immune stimulatory properties of K and D type ODNs in liposomes
were investigated in two different contexts.
It was previously shown that encapsulation of CpG ODNs into liposomes can
improve both immunostimulatory activity and uptake by immune cells in vitro and
in vivo [115]. Besides, liposome encapsulated CpG ODNs had promising adjuvant
effects [115, 113]. Hence, we aimed to analyze effects of liposomal introduction of
CpG ODNs to RAW 264.7 cells on critical proinflammatory cytokine genes IL1β
and IL6, as well as chemokines IP10 and MIP1α and TLR9, receptor evolved
for sensing unmethylated CpG motifs. We choose these readouts because earlier
studies reproducibly proved that ODN treatment triggers pro-inflammatory and
inflammatory response as well as TH1 biased immunity [116]. We have used
anionic liposomes for D35 and neutral liposomes for K3 based on a previous
study in our lab [113]. We were able to show that anionic liposome encapsulated
D35, but not control sequence or non-encapsulated D35 can induce prolonged and
pronounced cytokine expression (Figure 4.1). This effect was clearly CpG specific
and liposomes contributed the augmentation of all these parameters tested on this
cell line. Besides, chemokine expression and TLR9 expression was boosted by
AL containing D35 (Figure 4.1). We were not able to capture those effects on
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NL encapsulating K3. In accordance with our findings, in 2001 Verthelyi et. al
supported our results as they demonstrated that optimum sequence specificity is
another element for this enhanced activity [53].
Our utmost aim for the first part of this thesis was testing augmented
vaccine adjuvant effects of CpG ODNs when they were coencapsulated with
helicobacter antigen into liposomes against helicobacter vaccine development to
control widespread infections. Consequently, after obtaining preliminary data on
liposomal CpG formulations, we then proceeded to in vitro splenocyte stimulation
assays with liposomal CpG ODNs co-encapsulating different type of CpG ODNs
in a dose dependent manner. Earlier studies suggested that coencapsulation of
different TLR ligands into one liposomal compartment might cause synergism
between them [113]. Moreover, due to discrepancy in human responses, which
is fairly reasonable since humans are out breed species, it is not realistic to
expect one type of CpG ODN can yield protective immunity against pathogens
in the majority of a cohort. Therefore, Klinman et. al. have used a cocktail
of CpG ODNs to immunize macaques against anthrax [117] and demonstrated
the benefit of administering three different type of CpG rather than using one.
Thus, we also co-encapsulated two different CpG ODNs into five different types
of liposomes. Co-encapsulated CpG ODNs were K23 along with K3, two K
type ODNs, both are strong inducers of proinflammatory cytokine expression in
splenocytes [118], and D3CB MB, a D type ODN along with 1466 A-core MB,
D-like ODN, with modest proinflammatory cytokine induction effects yet they are
type I IFN inducers [113]. Furthermore, we serially diluted CpG ODNs to find the
lowest dose that was active in vitro. Our results, as expected, revealed that, at
high doses, liposome incorporation did not contribute to IL6 and IL12 production.
However, as we titrated the ODN concentration, liposomal CpG ODN mixtures
yielded reliable amounts of IL6 and IL12 where free counterparts lost their effect
(Figures 4.2, 4.3, 4.4 ad 4.5). This phenomenon was also observed by Erikci et.
al. [113]. IL6 secretion at low doses was most pronounced when K23&K3 mixture
in anionic liposomes was given to splenocytes. For the 1466&D3CG mixture,
best performing liposomal formulations were cationic and SSCL. Consistently,
67
anionic liposomes and cationic liposomes in addition to SSCL were the most
potent formulas for IL12 secretion, for K23&K3 and 1466&D3CG, respectively.
IL10 was among tested cytokines. There was a correlation between high levels of
IL10 secretion and H. pylori induced gastritis [119], which is probably due to Treg
activity [120, 121]. We found that liposomal CpG ODNs did not increase IL10
levels significantly compared to free counterpart irrespective of ODN type tested
(Figure 4.6).
Consequently, we tested our most prominent liposomal CpG ODN formulations
against H. felis. CpG ODNs and H. felis antigen were co-encapsulated into
liposomes and mice were immunized with these formulas. Total cell lysate was
used as antigen. Primary response, probably due to presence of several TLR
ligands in H. felis antigen, indicated that, all formulations induced an Ig response
(Figure 4.7). Secondary response after booster injection analyses revealed that Ag
+ ODN combination were as effective as liposomal counterparts (Figure 4.8). This
unexpected result probably was due to the Ag and CpG dose that we selected. In
this study, the amounts were 15 µg each for Ag and CpG per mouse. This was
considerably higher that doses that were used in a previous study [122]. There,
cholera toxin + CpG + Ag were used (10µg + 15 + 10µg per mouse). In our study
we have decided 15 + 15 µg for Ag and CpG (free and liposomal). After seeing our
results, it would have been more appropriate to reduce Ag and CpG dose. Only
then we would be able to detect the effect of liposome encapsulation. This study
is still ongoing. We are following the persistence of the antibody response against
H. felis and our results indicated that free CpG + Ag dependent anti H. felis
response tends to drop more faster than liposomal formulations (Figure 4.9). At
this stage, it is fair to say that including liposomes improves antigenicity against
H. felis compared to free combinations.
Final part of this thesis focused to overcome contrasting activity of
simultaneous K and D CpG ODNs usage on PBMC. After the demonstration of
unique features of D and further understanding of batch to batch variation problem
that led to abandoning D ODN specific clinical trials [123], researchers attempted
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to design new ODN classes resembling to D sequences, such as Y ODN, C type
ODN or P ODN [58, 60, 55]. Yet their simultaneous usage failed to recapitulate
the dual effect (i.e. K + D ODN effect). Alternatively, Honda et al used cationic
liposomes complexed with K ODN in 2005 and demonstrated IFNa secretion
from PBMCs [61]. Even this attempt did not broaden the spectrum of K + D
ODN usage, since it only mimicked D ODN-like effect. In our novel approach,
we tried to utilize both ODNs encapsulated in different liposomes and tested
them simultaneously on peripheral blood. Our data strongly suggest that putting
D35 ODN in anionic liposomes and co-incubating with liposomal K3 improved
K ODN specific effect and putting K3 in cationic liposomes and coincubating
with liposomal D35 improved D ODN effect. In two different trials, TNFa and
IL6 secretion was increased when K in liposomes combined with D35 in anionic
liposome (Figures 4.12 and 4.11 for first trial and Figures 4.16 and 4.15 for second
trial). We also succeeded to recapitulate D ODN specific effect and even augment
it when K3 in cationic liposomes and D35 in liposomes were simultaneously given
to human PBMC (Figures 4.14 and 4.18) It was known that K and D ODNs have
differential immune stimulatory activities as K ODN localizes to late endosome and
rapidly promotes pDC maturation, whereas D ODN localizes to early endosomal
compartments in where it induces IFNa expression [63, 62]. In case of simultaneous
administration to PBMCs, despite uptake kinetics are not effected, maturation
pDCs cancels D ODN specific effect [63, 62]. Or data suggests that we were able
to change intracellular fate of D and K type ODNs by encapsulating them into
specific liposome types and successfully overcome D and K ODN dichotomy.
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Chapter 6
Future perspectives
In this study, the first time liposomal CpG formulations were tested against H.
felis in an vaccination study, after conferring best in vitro performing formulations.
Yet, efficacy of liposomal formulations did not surpass free counterparts. However,
liposomal formulations tend to induce more stabile response. The more prolonged
study was required to further confirm this results. Moreover, we lacked proper
reagents to check IgA levels; a major antibody type for mucosal immunity. An
assay to determine IgA levels would increase confidence of our results. Besides, in
order to test potential of liposomal CpG ODNs as protective reagents, a pathogen
challenge could be done to immunized mice some time after booster injection.
In the second part, we were able to capture both K type CpG ODN specific
and D type CpG ODN specific effects when we combine proper liposomal K and D
type ODNs (i.e. anionic D35 and cationic K3). We speculated that this effect was
due to altered subcellular compartmentalization of K type ODN K3. As a follow
up study, one can test this hypothesis in vitro and in vivo, by using appropriate
dyes to monitor uptake and internalization of liposomal K3 and free K3 ODN
along with liposomal D35 ODN and free D35 ODN. This would allow to confirm
liposomes can change subcellular fates of K and D type CpG ODNs and their
effects can be combined for broader range of immune stimulation. Working K and
D CpG ODN dichotomy in mice with suitable reagents that we lack would be
another option to develop our results.
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Figure A.1: IgG levels of individual mouse immunized against H. felis 2 weeks
after 1st injection. Mice (5 mice/group) were immunized against H. felis with
CpG ODN and H. felis total cell extract or liposomes that co-encapsulate CpG
ODN and H. felis total cell extract. IgG levels were detected with IgG ELISA.
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Figure A.2: Mean IgG levels of mice immunized against H. felis 2 weeks after 1st
injection. Mice (5 mice/group) were immunized against H. felis with CpG ODN
and H. felis total cell extract or liposomes that co-encapsulate CpG ODN and H.
felis total cell extract. IgG levels were detected with IgG ELISA.
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Figure A.3: IgG1 levels of individual mouse immunized against H. felis 2 weeks
after 1st injection. Mice (5 mice/group) were immunized against H. felis with
CpG ODN and H. felis total cell extract or liposomes that co-encapsulate CpG
ODN and H. felis total cell extract. IgG1 levels were detected with IgG1 ELISA.
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Figure A.4: Mean IgG1 levels of mice immunized against H. felis 2 weeks after 1st
injection. Mice (5 mice/group) were immunized against H. felis with CpG ODN
and H. felis total cell extract or liposomes that co-encapsulate CpG ODN and H.
felis total cell extract. IgG1 levels were detected with IgG1 ELISA.
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Figure A.5: IgG2a levels of individual mouse immunized against H. felis 2 weeks
after 1st injection. Mice (5 mice/group) were immunized against H. felis with CpG
ODN and H. felis total cell extract or liposomes that co-encapsulate CpG ODN
and H. felis total cell extract. IgG2a levels were detected with IgG2a ELISA.
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Figure A.6: Mean IgG2a levels of mice immunized against H. felis 2 weeks after
1st injection. Mice (5 mice/group) were immunized against H. felis with CpG
ODN and H. felis total cell extract or liposomes that co-encapsulate CpG ODN
and H. felis total cell extract. IgG2a levels were detected with IgG2a ELISA.
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Figure A.7: IgG levels of individual mouse immunized against H. felis 2 weeks
after booster injection. Mice (5 mice/group) were immunized against H. felis with
CpG ODN and H. felis total cell extract or liposomes that co-encapsulate CpG
ODN and H. felis total cell extract. IgG levels were detected with IgG ELISA.
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Figure A.8: Mean IgG levels of mice immunized against H. felis 2 weeks after
booster injection. Mice (5 mice/group) were immunized against H. felis with CpG
ODN and H. felis total cell extract or liposomes that co-encapsulate CpG ODN
and H. felis total cell extract. IgG levels were detected with IgG ELISA.
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Figure A.9: IgG1 levels of individual mouse immunized against H. felis 2 weeks
booster 1st injection. Mice (5 mice/group) were immunized against H. felis with
CpG ODN and H. felis total cell extract or liposomes that co-encapsulate CpG
ODN and H. felis total cell extract. IgG1 levels were detected with IgG1 ELISA.
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Figure A.10: Mean IgG1 levels of mice immunized against H. felis 2 weeks after
booster injection. Mice (5 mice/group) were immunized against H. felis with CpG
ODN and H. felis total cell extract or liposomes that co-encapsulate CpG ODN
and H. felis total cell extract. IgG1 levels were detected with IgG1 ELISA.
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Figure A.11: IgG2a levels of individual mouse immunized against H. felis 2 weeks
after booster injection. Mice (5 mice/group) were immunized against H. felis with
CpG ODN and H. felis total cell extract or liposomes that co-encapsulate CpG
ODN and H. felis total cell extract. IgG1 levels were detected with IgG1 ELISA.
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Figure A.12: Mean IgG2a levels of mice immunized against H. felis 2 weeks after
booster injection. Mice (5 mice/group) were immunized against H. felis with CpG
ODN and H. felis total cell extract or liposomes that co-encapsulate CpG ODN
and H. felis total cell extract. IgG2a levels were detected with IgG2a ELISA.
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Figure A.13: IgG levels of individual mouse immunized against H. felis 6 weeks
after booster injection. Mice (5 mice/group) were immunized against H. felis with
CpG ODN and H. felis total cell extract or liposomes that co-encapsulate CpG
ODN and H. felis total cell extract. IgG levels were detected with IgG ELISA.
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Figure A.14: Mean IgG levels of mice immunized against H. felis 6 weeks after
booster injection. Mice (5 mice/group) were immunized against H. felis with CpG
ODN and H. felis total cell extract or liposomes that co-encapsulate CpG ODN
and H. felis total cell extract. IgG levels were detected with IgG ELISA.
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Figure A.15: IgG1 levels of individual mouse immunized against H. felis 6 weeks
booster 1st injection. Mice (5 mice/group) were immunized against H. felis with
CpG ODN and H. felis total cell extract or liposomes that co-encapsulate CpG
ODN and H. felis total cell extract. IgG1 levels were detected with IgG1 ELISA.
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Figure A.16: Mean IgG1 levels of mice immunized against H. felis 6 weeks after
booster injection. Mice (5 mice/group) were immunized against H. felis with CpG
ODN and H. felis total cell extract or liposomes that co-encapsulate CpG ODN
and H. felis total cell extract. IgG1 levels were detected with IgG1 ELISA.
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Figure A.17: IgG2a levels of individual mouse immunized against H. felis 6 weeks
after booster injection. Mice (5 mice/group) were immunized against H. felis with
CpG ODN and H. felis total cell extract or liposomes that co-encapsulate CpG
ODN and H. felis total cell extract. IgG1 levels were detected with IgG1 ELISA.
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Figure A.18: Mean IgG2a levels of mice immunized against H. felis 6 weeks after
booster injection. Mice (5 mice/group) were immunized against H. felis with CpG
ODN and H. felis total cell extract or liposomes that co-encapsulate CpG ODN
and H. felis total cell extract. IgG2a levels were detected with IgG2a ELISA.
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